Group 1 - The company announced a share repurchase plan on February 20, 2025, with a total amount not less than 20 million yuan and not exceeding 30 million yuan, at a maximum price of 23.84 yuan per share [1] - As of August 31, 2025, the company has repurchased a total of 197,500 shares, accounting for 0.17% of the current total share capital, with the highest transaction price being 16.05 yuan [1] - The company plans to continue the share repurchase based on market conditions within the approved timeframe and will fulfill information disclosure obligations as required [1]

格隆汇9月3日丨共同药业(300966.SZ)公布，截至2025年8月31日，公司本次通过股份回购专用证券账户 以集中竞价交易方式累计回购公司股份197,500股，占公司当前总股本的0.17%，最高成交价为16.05元/ 股，最低成交价为13.15元/股，成交总金额为302.9925万元(不含交易费用)。责任编辑：山上 ...

Core Viewpoint - The company, Gongtong Pharmaceutical, has announced a share buyback program, indicating confidence in its stock value and future prospects [1] Summary by Categories Share Buyback Details - As of August 31, 2025, the company has repurchased a total of 197,500 shares through a dedicated securities account via centralized bidding, which represents 0.17% of the company's current total share capital [1] - The highest transaction price during the buyback was 16.05 yuan per share, while the lowest was 13.15 yuan per share [1] - The total amount spent on the buyback was approximately 3.029925 million yuan, excluding transaction fees [1]

Core Viewpoint - The company has repurchased a total of 197,500 shares, representing 0.17% of its current total share capital, as part of its share buyback plan [1] Summary by Categories Share Buyback Details - The repurchase was conducted through a dedicated securities account via centralized bidding [1] - The highest transaction price was 16.05 CNY per share, while the lowest was 13.15 CNY per share [1] - The total amount spent on the repurchase was 3.0299 million CNY, excluding transaction fees [1] Compliance and Future Plans - The repurchase complies with relevant laws and regulations, as well as the company's share buyback plan requirements [1] - The company intends to continue implementing the buyback plan within the designated timeframe and will fulfill its information disclosure obligations promptly [1]

关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 | 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-051 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 湖北共同药业股份有限公司（以下简称"公司"）于 2025 年 2 月 20 日召开第 三届董事会第三次会议、第三届监事会第三次会议，审议通过了《关于回购公司股 份方案的议案》，同意公司使用自有资金及股票回购专项贷款资金以集中竞价交易 方式回购公司已发行的股份，用于股权激励或员工持股计划。本次回购总金额不低 于人民币 2,000 万元（含）且不超过人民币 3,000 万元（含），回购价格不超过 23.84 元/股，具体回购资金总额以回购期满时实际回购股份使用的资金总额为准，回购期 限为董事会审议通过该回购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 2 月 20 日、2025 年 2 月 26 日在巨潮资讯网（www.cninfo.com.cn）上披露的《关 ...

Core Insights - The company reported a revenue increase but a significant decline in net profit for the first half of 2025, indicating challenges in profitability despite higher sales [1] - The gross margin improved, but the net margin remained negative, reflecting ongoing financial pressures [1][3] Financial Performance - Total revenue for the first half of 2025 reached 302 million yuan, a year-on-year increase of 29.33% compared to 234 million yuan in 2024 [1] - The net profit attributable to shareholders was -11.15 million yuan, a decline of 117.88% from -5.12 million yuan in the previous year [1] - The gross margin improved to 21.77%, up 25.25% from 17.38% in 2024, while the net margin was -4.85%, down 64.53% from -2.95% [1] - Total expenses (selling, administrative, and financial) amounted to 54.49 million yuan, accounting for 18.02% of revenue, an increase of 16.2% year-on-year [1] Cash Flow and Debt - Cash and cash equivalents decreased by 56.02% to 134 million yuan, raising concerns about liquidity [1] - Accounts receivable increased by 21.72% to 239 million yuan, indicating potential cash flow issues [1] - Interest-bearing liabilities rose by 13.65% to 1.227 billion yuan, contributing to a higher debt burden [1][3] Business Model and Market Position - The company has established a vertical integration system covering the entire steroid drug industry chain, positioning itself as a key player in the domestic market [4][5] - The company aims to maintain its market share in the steroid drug sector through innovation and strategic partnerships with leading pharmaceutical companies [4][5] - Focus areas include reducing production costs through technological advancements and expanding capacity for high-value products [5]

Core Viewpoint - The company reported a significant increase in revenue but a substantial decline in net profit during the reporting period [1] Financial Performance - The company achieved operating revenue of 302.40 million yuan, representing a year-on-year growth of 29.33% [1] - The net profit attributable to shareholders was -11.15 million yuan, a decrease of 117.88% compared to the same period last year [1] Product Sales - Revenue from self-produced products increased by 44.71% year-on-year, with a gross margin improvement of 3.78% [1] - Revenue from non-self-produced products decreased by 36.74% year-on-year, with a gross margin decline of 1.40% [1] Financial Costs - The interest on convertible bonds included in financial expenses amounted to 14.68 million yuan, which had a certain impact on net profit [1]

湖北共同药业股份有限公司 章程修订对照表 为全面贯彻落实最新法律法规及规范性文件要求，进一步提升公司治理 水平，根据《中华人民共和国公司法》及《上市公司章程指引》《深圳证券 交易所创业板股票上市规则》等相关法律法规规定并结合公司实际情况，拟 对《公司章程》相关条款进行修订。 湖北共同药业股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日 召开第三届董事会第八次会议，审议通过了《关于修订<公司章程>的议 案》，该议案尚需提交公司 2025 年第一次临时股东大会审议，经出席会议的 股东所持表决权的三分之二以上通过方可生效。具体修订情况如下： | 原章程内容 | 修订后内容 | | --- | --- | | 第一条 | 第一条 | | 为维护公司、股东和债权人的合法权益，规范 | 为维护公司、股东、职工和债权人的合法权益，规范 | | 公司的组织和行为，根据《中华人民共和国公 | 公司的组织和行为，根据《中华人民共和国公司法》 | | 司法》(以下简称《公司法》)、《中华人民共 | （以下简称《公司法》）、《中华人民共和国证券 | | 和国证券法》(以下简称《证券法》)、《中国 | 法》（以下简称 ...

2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 | 编制单位：湖北共同药业股份有限公司 | 2025 年 06 月 30 日 | 单位：元 | | --- | --- | --- | | 项目 | 期末余额 | 期初余额 | | 流动资产： | | | | 货币资金 | 133,827,483.67 | 141,181,205.23 | | 结算备付金 | 0.00 | 0.00 | | 拆出资金 | 0.00 | 0.00 | | 交易性金融资产 | 1,010.70 | 1,010.63 | | 衍生金融资产 | 0.00 | 0.00 | | 应收票据 | 18,481,550.85 | 15,969,258.05 | | 应收账款 | 239,393,977.46 | 188,668,396.08 | | 应收款项融资 | 4,827,537.43 | 9,623,992.21 | | 预付款项 | 4,653,629.39 | 10,721,612.30 | | 应收保费 | 0. ...

上市公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：湖北共同药业股份有限公司 单位：人民币万元 | 非经营性资金占用 | 资金占用方 | 占用方与上 市公司的关 | 上市公司 核算的会计 | 2025年期初 占用资金余 | 年半年度占 2025 用累计发生金额 | 年半年度 2025 占用资金的利 | 年半年 2025 度偿还累计 | 年半年度期 2025 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 名称 | | | | | | | 末占用资金余额 | 原因 | 占用性质 | | | | 联关系 | 科目 | 额 | （不含利息） | 息（如有） | 发生金额 | | | | | 控股股东、实际控制人 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 非经营性占用 | | 及其附属企业 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 非经营性占用 | | 小计 | | ...